Advertisement
Advertisement
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
3.05
USDSponsored
-0.10
-3.17%
May 13, 15:59 UTC -4
Closed
Pre-Market
3.04
0.00
-0.16%
RXRX Earnings Reports
Positive Surprise Ratio
RXRX beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$13.35M
/-$0.26
Implied change from Q1 26 (Revenue/ EPS)
+106.22%
/+18.18%
Implied change from Q2 25 (Revenue/ EPS)
-30.57%
/-36.59%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On May 06, 2026, RXRX reported earnings of -0.22 USD per share (EPS) for Q1 26, beating the estimate of -0.27 USD, resulting in a 20.55% surprise. Revenue reached 6.47 million, compared to an expected 16.09 million, with a -59.78% difference. The market reacted with a +1.78% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 13.35 million USD, implying an increase of 18.18% EPS, and increase of 106.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.22, beating estimates by 20.55%, and revenue of $6.47M, -59.78% below expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved up 1.78%, changed from $3.37 before the earnings release to $3.43 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 7
analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.26 and revenue of $13.35M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement